If an athlete has a high calcium score on a heart scan (over 100), doctors should treat them like someone with early heart disease — lower their bad cholesterol and test how their heart handles exercise.
Scientific Claim
Athletes with coronary artery calcium (CAC) scores greater than 100 Agatston units should be managed similarly to non-athletes with preclinical atherosclerosis, including aggressive LDL-C lowering to <70 mg/dL and symptom-limited exercise testing.
Original Statement
“Until additional studies are available, we suggest that athletes with CAC values > 100 Agatston units be managed as if they have preclinical ASCVD. [...] aggressive lipid treatment to achieve low-density lipoprotein cholesterol (LDL-C) values < 70 mg/dl.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The authors explicitly state 'until additional studies are available' and use 'suggest' — correctly framing this as a provisional recommendation based on extrapolation, not direct evidence in athletes.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether achieving LDL-C <70 mg/dL in athletes with CAC >100 reduces major cardiovascular events compared to less aggressive targets.
Whether achieving LDL-C <70 mg/dL in athletes with CAC >100 reduces major cardiovascular events compared to less aggressive targets.
What This Would Prove
Whether achieving LDL-C <70 mg/dL in athletes with CAC >100 reduces major cardiovascular events compared to less aggressive targets.
Ideal Study Design
A double-blind RCT of 1,200 asymptomatic masters athletes (age 50–70) with CAC >100, randomized to LDL-C target <70 mg/dL (high-intensity statin ± ezetimibe) vs. <100 mg/dL (moderate statin), with primary endpoint of MACE over 5 years.
Limitation: Ethical and logistical challenges; long duration; high cost; may not reflect real-world adherence.
Prospective Cohort StudyLevel 2aWhether athletes with CAC >100 who achieve LDL-C <70 mg/dL have lower rates of progression or events than those who do not.
Whether athletes with CAC >100 who achieve LDL-C <70 mg/dL have lower rates of progression or events than those who do not.
What This Would Prove
Whether athletes with CAC >100 who achieve LDL-C <70 mg/dL have lower rates of progression or events than those who do not.
Ideal Study Design
A 7-year prospective cohort of 2,000 athletes with CAC >100, tracking LDL-C levels, statin use, and MACE, stratifying by achieved LDL-C (<70 vs. ≥70 mg/dL), adjusting for fitness, diet, and adherence.
Limitation: Observational; residual confounding by statin indication or lifestyle factors.
Cross-Sectional Imaging StudyLevel 3Whether athletes with CAC >100 and LDL-C <70 mg/dL have slower plaque progression than those with higher LDL-C.
Whether athletes with CAC >100 and LDL-C <70 mg/dL have slower plaque progression than those with higher LDL-C.
What This Would Prove
Whether athletes with CAC >100 and LDL-C <70 mg/dL have slower plaque progression than those with higher LDL-C.
Ideal Study Design
A 3-year longitudinal imaging study of 300 athletes with CAC >100, undergoing serial CAC and CTA scans, comparing plaque volume change between those achieving LDL-C <70 vs. ≥70 mg/dL.
Limitation: Does not measure clinical events; surrogate endpoint only.
Evidence from Studies
Supporting (1)
Coronary Atherosclerosis in Masters Athletes: Mechanisms and Implications for Cardiovascular Disease Risk
The study says that athletes with high calcium scores in their heart arteries should be treated the same way as non-athletes with early heart disease — by lowering bad cholesterol and testing their heart under stress. So yes, it supports the claim.